PT  - JOURNAL ARTICLE
AU  - Char Leung
TI  - Estimating the distribution of the incubation period of 2019 novel coronavirus (COVID-19) infection between travelers to Hubei, China and non-travelers
AID  - 10.1101/2020.02.13.20022822
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.02.13.20022822
4099  - http://medrxiv.org/content/early/2020/02/18/2020.02.13.20022822.short
4100  - http://medrxiv.org/content/early/2020/02/18/2020.02.13.20022822.full
AB  - Objectives Amid the continuing spread of the novel coronavirus (COVID-19), the incubation period of COVID-19 should be regularly re-assessed as more information is available upon the increase in reported cases. The present work estimated the distribution of incubation periods of patients infected in and outside Hubei province of China.Methods Clinical data were collected from the individual cases reported by the media as they were not fully available on the official pages of the Chinese health authorities. MLE was used to estimate the distributions of the incubation period.Results It was found that the incubation period of patients with no travel history to Hubei was longer and more volatile.Conclusion It is recommended that the duration of quarantine should be extended to at least 3 weeks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available in the public domain.